Immune checkpoint inhibitors in cancer therapy

Y Shiravand, F Khodadadi, SMA Kashani… - Current …, 2022 - mdpi.com
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

DR Wang, XL Wu, YL Sun - Signal transduction and targeted therapy, 2022 - nature.com
Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Combination strategies to maximize the benefits of cancer immunotherapy

S Zhu, T Zhang, L Zheng, H Liu, W Song, D Liu… - Journal of hematology & …, 2021 - Springer
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

Advances in antibody-based therapy in oncology

S Zinn, R Vazquez-Lombardi, C Zimmermann, P Sapra… - Nature cancer, 2023 - nature.com
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

Therapeutic targeting of the tumor microenvironment

L Bejarano, MJC Jordāo, JA Joyce - Cancer discovery, 2021 - AACR
Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

[HTML][HTML] Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

KL Banta, X Xu, AS Chitre, A Au-Yeung, C Takahashi… - Immunity, 2022 - cell.com
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …

Immunotherapy: reshape the tumor immune microenvironment

B Lv, Y Wang, D Ma, W Cheng, J Liu, T Yong… - Frontiers in …, 2022 - frontiersin.org
Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

H Raskov, A Orhan, JP Christensen… - British journal of cancer, 2021 - nature.com
The functions of, and interactions between, the innate and adaptive immune systems are
vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most …

Immunotherapy in lung cancer: current landscape and future directions

H Mamdani, S Matosevic, AB Khalid, G Durm… - Frontiers in …, 2022 - frontiersin.org
Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …